ArticleThe oncologist2024

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.

Rana R McKay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.